Comorbidity independently predicted death in older prostate cancer patients, more of whom died with than from their disease

被引:30
作者
Fouad, MN
Mayo, CP
Funkhouser, EM
Hall, HI
Urban, DA
Kiefe, CI
机构
[1] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL 35294 USA
[2] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30329 USA
[3] VAMC, Birmingham, AL USA
关键词
prostate cancer; comorbidity; mortality; retrospective studies; prostatic neoplasms/EH (ethnology); prostatic neoplasms/EP (epidemiology);
D O I
10.1016/j.jclinepi.2003.11.009
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: The purpose of this study was to examine the proportion of men who died from prostate cancer (PrCa) vs. with PrCa and assess the comorbid conditions associated with other-cause deaths. Study Design and Setting: We identified all male decedents aged greater than or equal to65 years in Jefferson County, AL, in 1993-1995. By crosslinking three databases (death certificate, Medicare, and Veteran's Administration), we identified men whose deaths might have been caused by PrCa. We abstracted and reviewed medical records to rate comorbid conditions and determine whether or not death was due to PrCa. Results: Of 561 men with a premortem diagnosis of PrCa, 42% died from PrCa and 53% died with PrCA; 50.2% of blacks died from PrCa vs. 36.9% of Whites. Other factors related to dying with PrCa included older age at death and a serious, or very serious, comorbid condition. Treatment did not have an independent effect on cause of death (i.e., death with vs. from PrCa). Conclusions: Comorbidity was an independent predictor of dying with PrCa, even after adjustment for ethnicity, age, and treatment. Given the as yet unproven benefit of PrCa screening, our results extend the body of information relevant to the screening decision; among men dying with a diagnosis of PrCa, only about 1/3 to 1/2 died from the disease. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:721 / 729
页数:9
相关论文
共 28 条
[1]   The impact of co-morbidity on life expectancy among men with localized prostate cancer [J].
Albertsen, PC ;
Fryback, DG ;
Storer, BE ;
Kolon, TF ;
Fine, J .
JOURNAL OF UROLOGY, 1996, 156 (01) :127-132
[2]   LONG-TERM SURVIVAL AMONG MEN WITH CONSERVATIVELY TREATED LOCALIZED PROSTATE-CANCER [J].
ALBERTSEN, PC ;
FRYBACK, DG ;
STORER, BE ;
KOLON, TF ;
FINE, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (08) :626-631
[3]  
[Anonymous], ONCOLOGY
[4]  
[Anonymous], 1997, ONCOLOGY WILLISTON P
[5]   LONG-TERM SURVIVAL AND MORTALITY IN PROSTATE-CANCER TREATED WITH NONCURATIVE INTENT [J].
AUS, G ;
HUGOSSON, J ;
NORLEN, L .
JOURNAL OF UROLOGY, 1995, 154 (02) :460-465
[6]  
Brawley OW, 1997, CANCER-AM CANCER SOC, V80, P1857, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1857::AID-CNCR26>3.0.CO
[7]  
2-3
[8]   Large-scale randomized prostate cancer screening trials:: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial [J].
de Koning, HJ ;
Auvinen, A ;
Sanchez, AB ;
da Silva, FC ;
Ciatto, S ;
Denis, L ;
Gohagan, JK ;
Hakama, M ;
Hugosson, J ;
Kranse, R ;
Nelen, V ;
Prorok, PC ;
Schröder, FH .
INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (02) :237-244
[9]   Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy [J].
Fowler, JE ;
Terrell, FL ;
Renfroe, DL .
JOURNAL OF UROLOGY, 1996, 156 (05) :1714-1718
[10]   THE IMPORTANCE OF COEXISTENT DISEASE IN THE OCCURRENCE OF POSTOPERATIVE COMPLICATIONS AND ONE-YEAR RECOVERY IN PATIENTS UNDERGOING TOTAL HIP-REPLACEMENT - COMORBIDITY AND OUTCOMES AFTER HIP-REPLACEMENT [J].
GREENFIELD, S ;
APOLONE, G ;
MCNEIL, BJ ;
CLEARY, PD .
MEDICAL CARE, 1993, 31 (02) :141-154